Chengdu Kanghong Pharmaceutical Group Co., Ltd.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. has seen a significant increase in its stock price today, contrasting with the broader market's performance. While the company has shown recent gains, its year-long performance reveals a decline. Financial metrics indicate a solid market capitalization and dividend yield, despite ongoing challenges.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. saw a significant rise in its stock on June 23, 2026, despite a broader market decline. The company has experienced mixed performance trends recently, with a notable year-to-date decline. It maintains a market capitalization of CNY 14,254 million and a dividend yield of 4.52%.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. saw a significant stock decline today, contrasting with broader market trends. The company has faced ongoing challenges, including a year-to-date drop and a notable decrease over the past decade. Financial metrics indicate mixed performance, with a recent decline in net profit.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. has seen notable stock activity, rising significantly today and showing a robust weekly increase. Despite a slight monthly decline, the company reported growth in net sales and achieved strong operating cash flow, highlighting its solid market position and operational efficiency in the pharmaceuticals sector.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. has experienced notable stock performance, achieving a significant weekly increase and an impressive annual return. The company maintains strong financial health, highlighted by high operating cash flow and a low debt-equity ratio, indicating solid operational capabilities and stability in the pharmaceuticals sector.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. saw a significant rise on March 6, 2026, outperforming the China Shanghai Composite. Over the past year, the company achieved a 43.28% return, despite recent short-term challenges. With a market cap of CNY 19,816 million, it maintains strong financial metrics and a high dividend yield.

Chengdu Kanghong Pharmaceutical Group Co., Ltd. faced a decline in stock performance, dropping 3.07% on March 3, 2026. Despite a year-to-date decrease, the company has shown strong resilience over the past year, with a return of 42.21%. Key financial metrics indicate a solid operational foundation.